Expression of Brca1 in mouse mammary cancer has yet to be analysed. We use a progressive model of neoplasia based on several mouse epithelial cell lines that represent distinct steps toward the fully tumorigenic state. Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1D11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary gland through pregnancy and involution. Expression of Brca1 was highest in rapidly proliferating cells. Expression of the full-length Brca1 was detectable in the virgin gland, was slightly elevated in the midpregnant gland, and decreased to levels similar to the age-matched virgin gland in the completely involuted gland. Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1D11, in tumors higher than those in the hyperplasias. While in disagreement with the observation that Brca1 levels decrease in human breast cancer progression, these patterns support the notion that Brca1 expression is associated with proliferating cells, and suggests that the link with dierentiation seen in normal cells can be removed when cells become tumorigenic.
Introduction
While the involvement of BRCA1 in sporadic breast cancer has yet to be convincingly demonstrated, mutations in this gene are thought to be responsible for about half of hereditary breast cancers, especially in families that also display ovarian cancers (Easton et al., 1993) . Cancers in women carrying a germline mutation in BRCA1 lose the normal copy of the gene, consistent with its characterization as a tumor suppressor gene (Merajver et al., 1995) . This hereditary breast cancer is characterized by an earlier age of detection and an increased incidence of tumors in both breasts (Lynch et al., 1994) . Tumors occurring in carriers tend to be highly proliferative and genetically unstable (Marcus et al., 1996) .
Although the function of BRCA1 is unknown, several lines of evidence point towards an involvement in DNA metabolism and/or cell cycle control. BRCA1 contains two protein motifs termed BRCT (Brca1 CTerminus) domains found in a wide variety of proteins associated with DNA damage repair (Bork et al., 1997; Callebaut and Mornon, 1997) . BRCA1 message is upregulated at the G1/S boundary in both normal and tumor derived cell lines (Vaughn et al., 1996) and the protein has been demonstrated to be a substrate of cdk2 and possibly cdk6 (Chen et al., 1996) . More tellingly, BRCA1 undergoes dierential phosphorylation in response to various DNA damaging agents (Thomas et al., 1997) and colocalizes with PCNA after DNA damage, presumably at the site of DNA repair (Scully et al., 1997b) . Perhaps most convincingly, Brca1 null cells have a defect in transcription-coupled repair of oxidative damage (Gowen et al., 1998) , and Brca1-de®cient cells show an increase in transcription-coupled repair after introduction of Brca1 (Abbott et al., 1999) . Also, BRCA1 gene expression has been shown to be upregulated in breast and ovarian cancer cell lines resistant to cisplatin, and these cell lines display increased capacity to repair DNA damage (Husain et al., 1998) . BRCA1 has also been shown to associate in S phase with Rad51, the mammalian homolog of RecA involved in recombination and repair (Scully et al., 1997a) . Even though BRCA1 levels can be stimulated by hormones (Marks et al., 1997) , this is thought to be an indirect eect resulting from mitogenic stimuli.
Several alternatively spliced forms of BRCA1 have been described, often lacking the large central exon 11 which contains the nuclear localization signals (Lu et al., 1996; Thakur et al., 1997) and resulting in cytoplasmic retention of the spliced form of the protein. Although overexpression of the full-length BRCA1 transcript has been reported to be toxic, overexpression of the major splice variant did not cause these problems . If alternative splicing events can regulate the available pool of functional BRCA1, it is possible that the shorter transcript may have a separate role in the cell. While all clearly disease-associated mutations in exon 11 result in a truncated protein product lacking the cterminal part of BRCA1, these mutations should not have any eect on the function of the protein produced from the spliced message. Because of this observation, the role of this alternate product may not be relevant to the tumor-suppressing properties of BRCA1, although at least one study has suggested that expression of shortened Brca1 in mouse ®broblasts leads to an increased sensitivity to apoptosis (Shao et al., 1996) .
Brca1 expression is necessary for development, as nullizygous mice die early in development (Gowen et al., 1996; Liu et al., 1996) . The mouse homolog, Brca1, is widely expressed during development in tissues that are proliferating rapidly and dierentiating (Lane et al., 1995; Marquis et al., 1995) suggesting that Brca1 may be involved in the functional dierentiation of tissues. In the adult animal Brca1 expression is high in organs with high cellular turnover, such as the testis and spleen. Expression of Brca1 at the RNA level correlates with PCNA protein staining (Blackshear et al., 1998) , in agreement with the idea that Brca1 expression is a characteristic of proliferating cells.
Because the expression pattern of Brca1 varies widely between cell lines, we analysed levels of Brca1 in the context of tumorigenesis. To achieve this end, we studied Brca1 expression in several mammary epithelial outgrowth lines passaged in vivo and their corresponding tumors. These lines were derived from the injection of immortalized cell lines into the cleared fat pads of syngeneic BALB/c mice (Medina et al., 1993 ) and represent preneoplastic cell populations which give rise to tumors at dierent rates depending upon the extent of accumulated genetic damage. The suggestion has been made that in human breast cancer, Brca1 expression is decreased compared to normal gland (Thompson et al., 1995) .
Results

Expression of Brca1 during normal development of the mammary gland
Because loss of wild-type Brca1 expression in the human strongly predisposes to breast cancer, we wanted to examine expression patterns during the normal development of the mouse mammary gland. Early reports indicated that Brca1 was upregulated in the pregnant gland and remained elevated after involution (Marquis et al., 1995; Rajan, et al., 1996) . This result raised the possibility that Brca1 expression might be related to the protective eect of early pregnancy against breast cancer.
We have generated probes to several regions of Brca1 and used them to test expression of Brca1 in pregnant, fully involuted, and virgin (age-matched to involuted) mammary gland by RNase protection assay. Levels of a housekeeping gene (actin or cyclophilin) were measured as an internal standard, and results were normalized to the level of the age-matched virgin in each case. The level of Brca1 expression in those age-matched virgins was sucient to allow regular detection. Consistently we observed expression in the mid-pregnant gland that was elevated over levels seen in the age-matched virgin gland (Figures 1 and 2 ). While only a twofold induction was observed in Balb/c mice, the levels of Brca1 in the FVB gland were elevated over fourfold, in line with what has been reported by others (Rajan et al., 1997) . Expression of Brca1 in the fully involuted gland, while often dicult to detect due to its low abundance, was present at an amount lower than that of the age-matched virgins. This pattern was observed in repeated experiments in both strains of mice (diculty in obtaining sucient signal strength and clarity to quantify expression, particularly in the fully involuted gland, led to the evaluation of Brca1 expression for the FVB strain from only three samples) (Figures 1 and 2 ). Elevation of Brca1 levels in the midpregnant gland over the virgin gland was signi®cant by Student's t-test (P50.05) and the decrease from the virgin gland to the involuted Figure 1 Expression of Brca1 through development of the normal mammary gland as determined by RNase protection assay. All samples are normalized to an internal control (actin or cyclophilin). Expression in the virgin gland (age-matched to involuted) is arbitrarily set to one. n=independent samples, bars represent standard error of the mean. Probe 5.36-BamHI used for FVB; combinations of 5.36-BamHI and pB2-EcoO1091 used for Balb/c Figure 2 Expression of full-length Brcal in the mammary gland through development as measured by RNase protection assay using probe 5.36-BamHI (a) Balb/c mice; lanes 1 and 2 virgin (age-matched to involuted); lanes 3 and 4 10 ± 13 day pregnant; lanes 5 and 6 5 weeks involuted (b) FVB mice; lanes 1 ± 3 virgin (age-matched to involuted); lanes 4 ± 6 10 ± 13 days pregnant; lanes 7 ± 9 5 weeks involuted Brca1/Brca1D11 RNA expression in mammary cancer M Mixon et al gland was also signi®cant (P50.05). The variation in Brca1 levels in the samples from the FVB mice mimicked the Balb/c trend and was also signi®cant for both midpregnant gland (P50.01) and involuted gland (P50.01).
In the beginning we suspected that perhaps the genetic background of the mice might have led to this unexpected result, but analysis of Brca1 expression in both the Balb/c mice we initially examined and the FVB strain examined in the previous report (Rajan et al., 1997) led to a similar pattern of expression ( Figure  2) . Figure 2 shows a probe speci®c to exon 11, p5.36-BamHI, that would not recognize the splice variant. The expression pattern we observed resembled the pattern seen by Blackshear et al. (1998) where no persistent elevation of Brca1 levels is noted in the involuted gland. Of six probes successfully used, three were entirely within exon 11, two were entirely 3' of exon 11, and one spanned the exon11/exon12 junction ( Figure 3 ). All of these probes gave similar results. Probes pB2-EcoO1019I and pB2-StuI recognized both the spliced Brca1 and the full-length message whereas probes pB3-EcoO109I, p5.36-NcoI, and p5.36-BamHI recognized only the full-length message. Probe pB1-HindIII spanned the exon11/12 junction and presumably recognized predominantly full-length message.
Isolation of the splice variant Brca1D11 from immortalized mouse epithelial cells
While several splice variants of Brca1 have been reported for the human, lacking various combinations of exons 9, 10, and 11 (Lu et al., 1996; Wilson et al., 1997; Xu et al., 1997) , it was not known whether this diversity in splicing would be re¯ected in the mouse. Initial RT ± PCR attempts to recover splice variants from total RNA isolated from pregnant mammary gland using a 20-mer primer set del11F and del11R were unsuccessful. However, utilizing poly(A) + RNA isolated from an immortalized, non-tumorigenic epithelial cell line FSK3 with a second series of longer primers able to withstand more vigorous reaction conditions, 35-mers del112F and del112AR, we were able to recover a single ampli®ed band. Either primer set used would theoretically have ampli®ed Brca1 species lacking exons 9 or 10 as well as part or all of exon 11. The failure to recover such transcripts may re¯ect diculty in amplifying such scarce transcripts rather than their absence. After subcloning into the pCR-II-TOPO vector (Invitrogen) to give pD11, the splice variant was sequenced and shown to contain exon 10 sequence linked directly to exon 12 which maintained the reading frame (Figure 4) . Sequencing of genomic DNA to get the exon 11 splice junction sequence showed that the junctions contained the consensus splice donor/acceptor signals GT/AG. This variant is expressed in a variety of mammary tissue types.
Expression of Brca1 and Brca1D11 in paired hyperplasias and tumors
Considering the diculty in isolating the Brca1 splice variant, we expected its level of expression to be low. Assuming that a low expression level of the splice variant would not confound results, we initially examined Brca1 expression in paired tumors and hyperplasias with a probe that recognizes both forms of Brca1. These outgrowth lines had diering potentials to form tumors, ranging from high (TM2H, TM4, TM6) to medium (TM10,TM12) to low (TM2L, TM3-1, TM3-2, TM40A) (Medina, 1996) . Brca1 expression was again measured by RNase protection assay ( Figure  5 ). Brca1 expression was seen in all nine pairs of hyperplasias and tumors, and the majority of paired hyperplasias and tumors (six of nine pairs) in the mouse show an increase in Brca1 transcripts in the tumors. When hyperplasias as a class are compared Figure 3 Probes used to detect Brca1 and Brca1D11
Oncogene Brca1/Brca1D11 RNA expression in mammary cancer M Mixon et al against tumors as a class, this increase is signi®cant (two-sided Student's t, P=0.05). Again it should be stressed that this re¯ects the total pool of Brca1, not only the full-length. This supports the idea that Brca1 expression is a re¯ection of proliferative capacity and can be decoupled from its normal context of dierentiation. Analysis of the RNA from these same samples was performed with a probe speci®c for Brca1D11. The protected fragment of this probe contains approximately equal portions from the 5' and 3' portions of the splice. Two regions of full-length sequence will be protected by this probe, but they will run at approximately 135 bp versus the 270 bp of the spliced form. Contrary to expectations, Brca1D11 was expressed at appreciable levels in the paired hyperplasias and tumors and its pattern of expression was slightly dierent than that of the total Brca1 pool ( Figure 6 ). This variant was expressed at a higher level in four of nine tumors. When all the tumors were considered as a group, the variant does not appear to be expressed at higher levels compared to hyperplasias as no signi®cant dierence in expression level was apparent.
To analyse relative abundance of the two transcripts, probes speci®c to Brca1D11 (pD11-AccI) and to Brca1 (p5.36-NcoI) were labeled so that the Brca1D11 protected fragment would have 10-fold higher speci®c activity than the Brca1 protected fragment and probed against RNA pools generated from at least six individual samples of paired tumor and hyperplasia. The presence of the Brca1D11 sequences in the full length Brca1 message leads to the generation of a doublet band running above the cyclophilin control. While the signal-to-noise ratio prevented quantitation of the relative levels of expression of the messages, it appears that the full-length form is two to ®ve times more abundant than the splice variant (Figure 7) . No change in relative levels of expression in the progression from hyperplasia to tumor is apparent.
Discussion
Our results indicate that expression of Brca1 is not upregulated in the fully involuted mammary gland. Several groups agree that levels of Brca1 rise during pregnancy (Lane et al., 1995; Marquis et al., 1995; Blackshear et al., 1998) ; however, there is some disagreement about the levels of Brca1 in the involuted gland. While variations in experimental approach may aect the outcome, the use of internal controls in our assays and the use of baseline virgins speci®cally agematched to our involuted samples should accurately re¯ect the natural levels of Brca1 at this timepoint. The fact that similar results were reproducibly obtained in two genetic backgrounds further supports our results.
Brca1 expression, while in general quite low, has been shown to be expressed in the mouse mammary gland during normal maturation caused by pregnancy and lactation as well as during the progression from preneoplasia to cancer. Brca1 expression increases As in vitro analysis of BRCA1 in cell lines has shown that levels are extremely low in cells in G0 (Vaughn et al., 1996) and the vast majority of the cells in the normal gland are not proliferating, it is likely that the increase in Brca1 expression during pregnancy is an indirect eect re¯ecting the increase in the proliferative compartment of the gland in response to elevated hormone levels occurring in pregnancy. It is still possible that the increased expression during pregnancy is a speci®c eect related to the dierentiation of the mammary gland, although the decrease in Brca1 levels after pregnancy suggests that this is not a lasting change. Although expression of BRCA1 has been found to be low in human breast cancer tumors from mutation carriers (Kainu et al., 1996) and levels reportedly decrease during the transition from DCIS to invasive cancer (Thompson et al., 1995) , expression in mouse mammary tumors has not been examined. As is the case with many aspects of BRCA1 analysis, this observation concerning expression during the progression from DCIS to invasive cancer is controversial and has been dicult to con®rm. Using established hyperplastic outgrowth lines that spontaneously form tumors at dierent frequencies, we monitored the expression of Brca1 in closely related populations during the transition to neoplasia. Contrary to what has been seen in the human situation, expression of Brca1 RNA does not decrease, but increases, in mouse spontaneous tumors as compared to their hyperplasias. While this analysis is only at the RNA level and does not guarantee a corresponding increase in protein, this is nevertheless a somewhat surprising result. This does support the idea that Brca1 expression is a consequence of proliferating cells, as the tumor cells are proliferating more rapidly than the hyperplasias (Jiang et al., 1997) , and suggests that the proliferative aspect of Brca1 can be decoupled from its normal association with dierentiation.
We have also examined a mammary-epithelial cell derived Brca1 splice variant that is expressed in the same tissues as the full-length message, but in a slightly dierent fashion. Although several alternatively spliced species are present in the human, only one was recovered from the mouse. While this variant and its human homologs are not well characterized, the initial idea that a variation in the ratio of spliced to fulllength Brca1, possibly suggesting a method of regulating the available pool of functional Brca1, might be observed either in the normal development of the gland or during tumorigenesis seems not to be applicable for the mouse mammary gland.
In conclusion, these results suggest that expression patterns of Brca1 RNA levels in mammary cancer may dier between mouse and human, with an increase in expression seen in the mouse. While an increase in expression of a tumor-suppressor gene as a common occurrence in unrelated tumors is somewhat unexpected, this may not translate to an increase in the amount of functional Brca1 protein through either inhibited mRNA translation or increased protein degradation. Alternatively, these tumors may have accumulated mutations that render them insensitive to the normal biological eects of Brca1. The presence of a spliced form of Brca1 in the mouse may represent one more level of post-transcriptional control for ®ne tuning Brca1 levels in the cell, but does not appear to be fundamentally dierent between hyperplasia and tumor. Certainly no dramatic dierence in Brca1 expression patterns between full-length and spliced were seen between tumors and hyperplasias. The expression of Brca1 through normal development of the mammary gland mirrors the amount of the gland that is proliferating, and may not be a discrete re¯ection of the parous versus nulliparous state. The failure of Brca1 levels to remain elevated after complete involution suggests that any role Brca1 plays in contributing to pregnancy-related protection from breast cancer is complicated and not simply a result of overexpression.
Materials and methods
Cell culture
FSK3 immortalized mammary epithelial cells, described previously (Kittrell et al., 1992) and routinely passaged in our laboratory are maintained in DMEM/F12 supplemented with 2% ABS, insulin (10 mg/ml), EGF (5 ng/ml), and gentamycin (5 mg/ml).
Tissues
The samples of normal mammary gland were taken from Balb/c that are bred and maintained in our animal facility and from FVB mice purchased from Charles Rivers Laboratories. For both strains, mammary gland was collected from virgin mice age-matched to 5 ± 6 weeks involuted primiparous mice and from 11 ± 14 day pregnant (primiparous) mice. The hyperplastic outgrowth tissue and primary tumors derived from the hyperplastic outgrowths were from Balb/c female mice (Kittrell et al., 1992) . All tumors were classi®ed as adenocarcinomas, type B.
RNA isolation
Total RNA was isolated from tissues and cells using RNAzol B (Tel Test) or TRIzol reagent (Gibco BRL) (Medina et al., 1998) . Tissues were homogenized in reagent with a Polytron homogenizer while cells were lysed directly in cell culture dishes. Poly(A) + RNA was isolated from total RNA using an Oligotex mRNA kit (QIAGEN).
Probes and plasmids
Plasmid pB2 was generated by cloning an RT ± PCR product generated from forward primer 5'-CAAACCTTTCTGAAG-ACTGC-3' and reverse primer 5'-TGAAGATGTCAATTCC-GGCT-3' (primers gift of J Rosen) into pGEM-T (Promega).
Restriction digestion with EcoO109I or StuI produced templates for the respective riboprobes. Plasmid pB3 was generated similarly using forward primer 5'-GAAGTATG-TTCCACTGGT-3' and reverse primer 5'-CATAGATTGCT-CAAGAAGG-3'. Digestion with EcoO109I provided template for the riboprobe pB3-EcoO109I. Plasmid 5.36 contains the 5' portion of the Brca1 cDNA up to the HindIII site (nt 3879) and was generated by combining the BamHI-ScaI fragment (nt 791 ± 1624) of clone 5.3 with the ScaI-HindIII fragment (nt 1624 ± 3879) of clone 6 (both cDNA clones provided by A Bradley) into BamHI-HindIII digested pBK-CMV (Stratagene). Digestion of 5.36 with BamHI and NcoI gives the template for the respective riboprobes. Probe pB1-HindIII is transcribed from clone 6 digested with HindIII. Probes for cyclophilin and actin were generated from pTRIactin and pTRI-cyclophilin (Ambion).
Antisense riboprobes were transcribed using the appropriate phage polymerase using 32 P-labeled CTP (Amersham, ICN) and either the Combination Riboprobe System T3/T7 (Promega) or the MAXIscript kit Sp6/T7 (Ambion) according to manufacturers instructions and gel puri®ed on 5% acrylamide 8 M urea gels. Riboprobes to actin and cyclophilin were labeled to 100-fold less speci®c activity than Brca1 probes.
Plasmid pD11 was generated by cloning the RT ± PCR product generated using the forward primer del112F 5'-TTGTGAGCGTTTGAATGAGGAGGCGTCGATCATCC-3' and the reverse primer del112AR 5'-CAGCTTCCAGGT-GAGCCATTTCCTGCTGCAGCTTT-3' and 0.1 mg polyA + RNA extracted from FSK3 cells into the pCRII-TOPO vector (Invitrogen).
The insert was sequenced at the University of Texas Health Science Center at Houston DNA sequencing facility using an ABI Prism. Sequencing of the exon 11 boundary junctions was done by ACGT Inc.
RNase protection assays
RNase protection assays were performed using the RPAII and RPAIII kits (Ambion), according to manufacturer's instructions (Medina et al., 1998) . Experiments were performed with equal amounts of total RNA using between 20 and 40 mg per series. In some series where the protected fragment was fractured into two smaller bands, these bands were summed to re¯ect total Brca1 levels. Avoiding temperatures over 958 and performing the RNase digestion step at room temperature has eliminated this problem.
